SFDA approves registration of 'Jascayd' for treatment of idiopathic pulmonary fibrosis

The Saudi Food and Drug Authority (SFDA) has approved the registration of Jascayd (nerandomilast) for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF) ...

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (saudigazette.com.sa)